61 results
6-K
EX-10.1
PRTG
Portage Biotech Inc
3 Oct 23
Current report (foreign)
4:05pm
U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).
(ll) U.S. Real Property Holding
424B5
PRTG
Portage Biotech Inc
2 Oct 23
Prospectus supplement for primary offering
6:01pm
of leading, world class universities and institutes, such as the Department of Investigative Medicine at University of Oxford, The National Cancer
6-K
EX-2.1
dci5lgzp7t2nc9rg2
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
at150odu1v8 t21
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-10.3
1bnruwwmxm
8 Jul 22
Current report (foreign)
8:58am
SUPPL
7q1t27g 21
24 Jun 21
Supplemental materials (foreign)
5:27pm
6-K
EX-99.1
wkt pnw8cw
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
6-K
EX-99.2
htcpc fbhdayium03y
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
6-K
EX-1.1
dhzlm8
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
SUPPL
eo8 t9uipr5lsq
23 Jun 21
Supplemental materials (foreign)
4:01pm
424B2
2yejfdnmvejjpxa
8 Mar 21
Prospectus for primary offering
5:00pm
F-3
nhs7448 nhtko2q8rdqw
24 Feb 21
Shelf registration (foreign)
5:22pm
F-3
EX-1.1
gce5z6nl epvn0ad7
24 Feb 21
Shelf registration (foreign)
5:22pm